Name: Wearable Cardioverter Defibrillators Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: MD3895
Price: 4350 USD
Availability: InStock

Wearable Cardioverter Defibrillators Market Size Share & Forecast 2030

Wearable Cardioverter Defibrillators Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Wearable Cardioverter Defibrillators Market is segmented By Conditions (Peripartum Cardiomyopathy, Congenital Heart Disease, Inherited Arrhythmias), By Implant Type (Implantable Cardioverter Defibrillator (ICD), External Cardioverter Defibrillator), By End-User (Home Care settings, Clinic, Outpatient Centres),&nbsp;By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

Wearable Cardioverter Defibrillators Market&nbsp;is estimated to reach&nbsp;at a <a href="https://www.datamintelligence.com/download-sample/wearable-cardioverter-defibrillators-market">CAGR of 25.45%</a> during the forecast period (2023-2030).&nbsp;The rechargeable external device wearable cardioverter defibrillator (WCD) can be worn under the clothing all day long and protects the user from potentially life-threatening ventricular tachyarrhythmias.

Wearable Cardioverter Defibrillators Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			25.45%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Conditions,&nbsp;By Implant Type,&nbsp;By End-User,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Market Dynamics</h3>

The increase in the prevalence of cardiovascular disease and increasing technological development is assumed to drive the wearable cardioverter-defibrillators in the forecast period.

The increase in the prevalence of cardiovascular disease is expected to drive the wearable cardioverter defibrillators market

The estimated study of Global Burden of Disease of age-standardized death rate of cardiovascular disease272 per 100,000 population in India is higher than the global average population. According to the Journal of the American College of Cardiology, the number of people dying from cardiovascular disease is rising steadily, globally including one-third of all deaths in 2019, that reviewed the total magnitude of CVD burden and trends over 30 years around the world. Implantable cardioverter defibrillators (ICDs) efficacy has been demonstrated by multiple clinical trials to prevent sudden cardiac death (SCD) among specific high-risk populations. Because of the increasing use of the wearable cardioverter defibrillators and uncertainty of indications among practicing cardiovascular health professionals, this science advisory was prepared by the American Heart Association.

The wearable cardioverter-defibrillator is an alternative antiarrhythmic device that provides continuous cardiac monitoring and defibrillation capabilities through a non-invasive, electrode-based system. The WCD is highly effective at restoring sinus rhythm in patients with ventricular tachyarrhythmia. Using the WCD one randomized trial in patients with recent myocardial infarction at increased risk for arrhythmic death reported a decrease in mortality overall despite no sudden cardiac death mortality benefit. The current clinical indications for WCD use vary and continue to evolve as experience with this technology increases.

The increasing technological development is assumed to drive the wearable cardioverter-defibrillators in the forecast period

The implantable cardioverter-defibrillator (ICD) is central in the prevention of sudden cardiac death (SCD). Current guidelines recommend ICD implantation for secondary and primary prevention in patients with an established high risk of SCD. Currently, only one WCD system (LifeVest&reg;, ZOLL, Pittsburgh, PA, USA) is available. The WCD is a system that consists of a harness-style vest that contains non-adhesive dry tantalum oxide capacitive sensing electrodes and self-gelling defibrillator electrodes. This lightweight vest (0.8 kg) is designed to be worn continuously under normal clothing and is available in different sizes. A monitor is worn around the waist (or shoulder harness) and contains sensing circuits, batteries, and capacitors. The device has a system of audible and vibratory alerts to warn a patient of an imminent shock. The patient can abort the shock by pressing buttons on the monitor.

Technological advances are considerable in cardiac pacing and defibrillation, from the latest venous accesses for implantation to recent locations for permanent pacing or non-endovenous ICD. The imagination of researchers and device companies seems to be limitless.

The lack of awareness and use of wearable cardioverter defibrillators is expected to hamper the market

Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardiac death, bridging a vulnerable period until a decision on implantable cardioverter-defibrillator (ICD) implantation can be reached. WCD is commonly used for three months or less. It is unknown which patients use WCD longer and which patients are most likely to benefit from it. Hypothesis. Extended use of WCD is reasonable in selected cases based on underlying heart disease and overall patient risk profile. Wearable devices can impact directly clinical decision-making. Some users think that wearable technologies improve the quality of patient care by reducing the cost. The big data generated by wearable devices is both a opportunity and challenge for researchers who can apply more artificial intelligence (AI) techniques to these in the future data. Most technologies are still in their prototype stages. Issues such as security ,user acceptance, big data and ethics concerns in this technology l need to be addressed still to enhance the functions and usability of these devices for practical use.

A wearable cardioverter defibrillator is an option for temporary therapy that can protect patients vulnerable to cardiac arrhythmias by preventing, aborting sudden cardiac death, and lowering mortality rates. Although there are barriers to overcome, promoting consistent identification and increasing awareness may increase the use of this life-saving therapy of these at high-risk, decrease the current gap in care, and improve clinical decision-making.

<h3>COVID-19 Impact Analysis</h3>

The healthcare industry has been affected by COVID-19. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has positively affected the wearable cardioverter defibrillators market as people can stay at home and get treated without visiting the doctor in person.

<h3>Segment Analysis</h3>

The Peripartum Cardiomyopathy segment is expected to dominate the wearable cardioverter defibrillators market

Peripartum cardiomyopathy is a heart muscle weakness that begins sometime during the final month of pregnancy through about five months after delivery, without any other known cause. It is now considered cardiomyopathy of an unknown cause that occurs in the peripartum period in women without pre-existing heart disease. Peripartum cardiomyopathy is relatively rare but devastating, with reported mortality rates between 18% and 56%.

Patients with peripartum cardiomyopathy (PPCM) have sudden cardiac death rates (SCD) of 7-56%; half of these occur &lt;12 weeks of delivery. Ventricular recovery occurs in 30 -50% of PPCM, often within six months. Implantable cardioverter-defibrillator (ICD) therapy is used for persistent ventricular dysfunction. SCD risk before ICD implant is unknown. Risk factors for PPCM include non-Caucasian race, gestational hypertension, twin pregnancy, multiparity, and older age. The WCD is composed of four dry, no adhesive electrodes for monitoring, incorporated into a chest strap assembly three defibrillation electrodes and a defibrillation unit carried on a waist belt. The monitoring electrodes are circumferentially positioned around the chest, held by tension from an elastic belt and provides two surface electrocardiogram (ECG) leads. In a vest assembly the defibrillation electrodes are positioned for apex-posterior defibrillation. Proper fitting is required to achieve adequate skin contact to avoid noise and frequent alarms. PPCM patients with severely reduced LVEF have an elevated risk for ventricular tachyarrhythmias early after diagnosis. Therefore, the use of the WCD should be considered in all women with early-stage PPCM and severely reduced LVEF during the first six months after initiation of heart failure therapy.

Implantable Cardioverter Defibrillator (ICD) dominated the wearable cardioverter defibrillators market

A battery-powered device, implantable cardioverter defibrillator that keeps track of the heart rate is placed under the skin. Thin wires connect the ICD to the heart. The device will deliver an electric shock if an abnormal heart rhythm is detected, to restore a normal heartbeat if the heart beats chaotically and too fast. They have been very useful in preventing sudden death in patients with sustained, known ventricular tachycardia or fibrillation. Studies have shown that they may prevent cardiac arrest in high-risk patients who haven&#39;t had it but are at life-threatening risk for ventricular arrhythmias. It is implanted under the skin, just under the collarbone. It detects arrhythmias and responds with electrical signals to restore your heart&#39;s normal rhythm.

They detect and stop arrhythmias. The device continuously monitors heartbeat and delivers electrical pulses to restore when necessary the heart rhythm to normal. It differs from a pacemaker&nbsp; another implantable device used to help control abnormal heart rhythms. It is placed surgically under skin, usually below the left collarbone. One or more flexible, insulated wires run from the ICD through veins to heart. Because the ICD monitors constantly for abnormal heart rhythms and instantly tries to correct them, it helps when the heart stops beating even when the patient is far from the nearest hospital. It has become standard treatment cardiac arrest, and are increasingly being used for high risk of sudden cardiac arrest. Sudden death from cardiac arrest can be lowered by ICD risk than medication alone.

The home care settings are assumed to dominate the market

As people mostly prefer home treatment and are spending much on resources to get better treatment at home. Since COVID-19 has made it difficult for patients to visit hospitals, it is easy for physicians to assist patients virtually due to advancements in technology. ZOLL LifeVest is used to detect a life-threatening rapid heart rhythm and automatically deliver a treatment shock to restore a normal rhythm. From detecting a rapid life-threatening heartbeat to automatically delivering a shock, the entire event takes usually less than a minute.

Wearable cardioverter defibrillators does not require the assistance of an emergency personnel or professional for it to work. It can protects patient even when they are alone. With a WCD, patients can continue to do many of the things like spending time without worrying with friends and family, about the risk of SCD. A patient should only remove their ZOLL LifeVest WCD while taking bath or a short shower. If possible, this should be done only when someone is home with the patient,.

<h3>Geographical Analysis</h3>

North America region is expected to dominate the wearable cardioverter defibrillators market

Due to the growing incidence of diseases, and healthcare system in this region is assumed to dominate the wearable cardioverter defibrillators market.

In the U.S, every 36 seconds a person dies from cardiovascular disease. About 655,000 Americans die from heart disease each year that&#39;s 1 in every four deaths. According to a report, nearly half of all U.S. adults have some type of cardiovascular disease, a percentage that reflects recently updated guidelines for treating high blood pressure. High blood pressure also known as hypertension &ndash; can lead to heart attack, heart failure and stroke.

On average than any other nation, the United States spends more on health care services than twice as much per person as the other countries. These expenditures are financed by a mixture of complex individual payments, public payers and private insurance There is no single system of health insurance nationwide. The U.S. healthcare system is characterized as the world&#39;s most expensive yet least effective compared with other nations. Major healthcare costs drivers are institutionalized medical practices ,technology-induced costs and consumer behavior reimbursement policies. Hence, the increasing incidence of heart diseases and advanced healthcare structures will increase the demand for wearable cardioverter-defibrillators.

<h3>Competitive Landscape</h3>

Major key players in the wearable cardioverter defibrillators market are ZOLL Medical Corporation, Medtronic, St. Jude Medical LLC, Boston Scientific Corporation, LivaNova, Koninklijke Philips N.V., Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation Defibtech LLC, Tianjin JingMing New Tech. Devp. Co., Ltd, HANSON MEDITEC CO., LTD and Huaian Meide Medical Instrument Co., Ltd

Wearable Cardioverter Defibrillators Market Key Companies to Watch

<h3>Cardiac Science Corporation</h3>

Overview: Cardiac Science Corporation develops, manufactures, and markets diagnostic and therapeutic cardiology products. The Company offers automated external defibrillators, diagnostic workstations, and systems. Cardiac Science serves patients worldwide.

Product Portfolio: Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems.

Key Development: ZOLL&reg; Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, confirmed that it has completed the previously announced acquisition of Cardiac Science&reg; Corporation, a leading provider of automated external defibrillators (AEDs), related services, and accessories.

The wearable cardioverter defibrillators market report would provide an access to an approx. 60 market data table, 50 figures and 180 pages.&nbsp; 

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/phonocardiograph-market">Phonocardiograph Market</a>

<a href="https://www.datamintelligence.com/research-report/trauma-fixation-devices-market">Trauma Fixation Devices Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>
		Market Snippet By Conditions
		</li>
		<li>
		Market Snippet By Implant Type
		</li>
		<li>
		Market Snippet By End-user
		</li>
		<li>
		Market Snippet By Region
		</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>
		Market Impacting Factors

		<ol>
			<li>
			Drivers

			<ol>
				<li>
				The increase in the prevalence of the cardiovascular disease is expected to drive the wearable cardioverter defibrillators market
				</li>
				<li>
				The increasing technological development is assumed to drive the wearable cardioverter defibrillators in the forecast period
				</li>
			</ol>
			</li>
			<li>
			Restraints:

			<ol>
				<li>
				The lack of awareness and use of wearable cardioverter defibrillators is expected to hamper the market
				</li>
			</ol>
			</li>
			<li>
			Opportunity
			</li>
			<li>
			Impact Analysis
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Epidemiology Analysis
		</li>
		<li>
		Supply Chain Analysis
		</li>
		<li>
		Pricing Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Reimbursement Analysis
		</li>
		<li>
		Unmet Needs
		</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>
		Analysis of Covid-19 on the Market

		<ol>
			<li>
			Before COVID-19 Market Scenario
			</li>
			<li>
			Present COVID-19 Market Scenario
			</li>
			<li>
			After COVID-19 or Future Scenario
			</li>
		</ol>
		</li>
		<li>
		Pricing Dynamics Amid Covid-19
		</li>
		<li>
		Demand-Supply Spectrum
		</li>
		<li>
		Government Initiatives Related to the Market During Pandemic
		</li>
		<li>
		Manufacturers Strategic Initiatives
		</li>
		<li>
		Conclusion&nbsp;
		</li>
	</ol>
	</li>
	<li>
	By Conditions

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions Segment
			</li>
			<li>
			Market Attractiveness Index, By Conditions Segment
			</li>
		</ol>
		</li>
		<li>
		Peripartum Cardiomyopathy *

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2020-2029
			</li>
		</ol>
		</li>
		<li>
		Congenital Heart Disease
		</li>
		<li>
		Inherited Arrhythmias
		</li>
	</ol>
	</li>
	<li>
	By Implant Type

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Attractiveness Index, By Implant Type
			</li>
		</ol>
		</li>
		<li>
		Implantable Cardioverter Defibrillator (ICD)*

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2020-2029
			</li>
		</ol>
		</li>
		<li>
		External Cardioverter Defibrillator
		</li>
	</ol>
	</li>
	<li>
	By End-user

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
			</li>
			<li>
			Market Attractiveness Index, By End-user Segment
			</li>
		</ol>
		</li>
		<li>
		Home Care settings *

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2020-2029
			</li>
		</ol>
		</li>
		<li>
		Clinic
		</li>
		<li>
		Outpatient Centres
		</li>
	</ol>
	</li>
	<li>
	By Region

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
			</li>
			<li>
			Market Attractiveness Index, By Region
			</li>
		</ol>
		</li>
		<li>
		North America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				U.S.
				</li>
				<li>
				Canada
				</li>
				<li>
				Mexico
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Europe

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Germany
				</li>
				<li>
				U.K.
				</li>
				<li>
				France
				</li>
				<li>
				Italy
				</li>
				<li>
				Spain
				</li>
				<li>
				Rest of Europe
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		South America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Brazil
				</li>
				<li>
				Argentina
				</li>
				<li>
				Rest of South America
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Asia Pacific

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				China
				</li>
				<li>
				India
				</li>
				<li>
				Japan
				</li>
				<li>
				Australia
				</li>
				<li>
				Rest of Asia Pacific
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Middle East and Africa

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>
		Key Developments and Strategies
		</li>
		<li>
		Company Share Analysis
		</li>
		<li>
		Product Benchmarking
		</li>
		<li>
		List of Key Companies to Watch
		</li>
		<li>
		List of Company with disruptive technology
		</li>
		<li>
		List of Start Up Companies
		</li>
	</ol>
	</li>
	<li>
	Company Profiles

	<ol>
		<li>
		Cardiac Science Corporation*

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Product Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		ZOLL Medical Corporation
		</li>
		<li>
		Medtronic
		</li>
		<li>
		St. Jude Medical LLC
		</li>
		<li>
		Boston Scientific Corporation
		</li>
		<li>
		Abbot Medical Optics
		</li>
		<li>
		LivaNova
		</li>
		<li>
		Tianjin JingMing New Tech. Devp. Co., Ltd
		</li>
		<li>
		HANSON MEDITEC CO., LTD
		</li>
		<li>
		Huaian Meide Medical Instrument Co., Ltd(*LIST NOT EXHAUSTIVE)&nbsp;
		</li>
	</ol>
	</li>
	<li>
	DataM Intelligence&nbsp;&nbsp;

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01 Wearable Cardioverter Defibrillators Market Value, By Conditions, 2021, 2025 &amp; 2029($ Million)

Table 02 Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2021, 2025 &amp; 2029($ Million)

Table 03 Wearable Cardioverter Defibrillators Market Value, By End-user, 2021, 2025 &amp; 2029($ Million)

Table 04 Wearable Cardioverter Defibrillators Market Value, By Conditions, 2021, 2025 &amp; 2029($ Million)

Table 05 Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 06 Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2021, 2025 &amp; 2029($ Million)

Table 07 Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 08 Wearable Cardioverter Defibrillators Market Value, By End-user, 2021, 2025 &amp; 2029($ Million)

Table 09 Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 10 Wearable Cardioverter Defibrillators Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 11 Wearable Cardioverter Defibrillators Market Value, By Region, 2019-2029 ($ Million)

Table 12 North America Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 13 North America Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 14 North America Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 15 North America Wearable Cardioverter Defibrillators Market Value, By Country, 2019-2029 ($ Million)

Table 16 South America Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 17 South America Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 18 South America Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 19 South America Wearable Cardioverter Defibrillators Market Value, By Country, 2019-2029 ($ Million)

Table 20 Europe Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 21 Europe Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 22 Europe Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 23 Europe Wearable Cardioverter Defibrillators Market Value, By Country, 2019-2029 ($ Million)

Table 24 Asia-Pacific Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 25 Asia-Pacific Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 26 Asia-Pacific Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 27 Asia-Pacific Wearable Cardioverter Defibrillators Market Value, By Country, 2019-2029 ($ Million)

Table 28 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Value, By Conditions, 2019-2029 ($ Million)

Table 29 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Value, By Implant Type, 2019-2029 ($ Million)

Table 30 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Value, By End-user, 2019-2029 ($ Million)

Table 31 St. Jude Medical LLC: Overview

Table 32 St. Jude Medical LLC: Product Portfolio

Table 33 St. Jude Medical LLC: Key Developments

Table 34 ZOLL Medical Corporation: Overview

Table 35 ZOLL Medical Corporation: Product Portfolio

Table 36 ZOLL Medical Corporation: Key Developments

Table 37 Medtronic: Overview

Table 38 Medtronic: Product Portfolio

Table 39 Medtronic: Key Developments

Table 40 Cardiac Science Corporation: Overview

Table 41 Cardiac Science Corporation: Product Portfolio

Table 42 Cardiac Science Corporation: Key Developments

Table 43 Boston Scientific Corporation: Overview

Table 44 Boston Scientific Corporation: Product Portfolio

Table 45 Boston Scientific Corporation: Key Developments

Table 46 Abbot Medical Optics: Overview

Table 47 Abbot Medical Optics: Product Portfolio

Table 48 Abbot Medical Optics: Key Developments

Table 49 LivaNova Overview

Table 50 LivaNova: Product Portfolio

Table 51 LivaNova: Key Developments

Table 52 Tianjin JingMing New Tech. Devp. Co., Ltd: Overview

Table 53 Tianjin JingMing New Tech. Devp. Co., Ltd: Product Portfolio

Table 54 Tianjin JingMing New Tech. Devp. Co., Ltd: Key Developments

Table 55 HANSON MEDITEC CO., LTD: Overview

Table 56 HANSON MEDITEC CO., LTD: Product Portfolio

Table 57 HANSON MEDITEC CO., LTD: Key Developments

Table 58 Huaian Meide Medical Instrument Co., Ltd: Overview

Table 59 Huaian Meide Medical Instrument Co., Ltd: Product Portfolio

Table 60 Huaian Meide Medical Instrument Co., Ltd: Key Developments

&nbsp;

List of Figures

Figure 01 Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 02 Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 03 Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 04 Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 05 Wearable Cardioverter Defibrillators Market Y-o-Y Growth, By Conditions, 2021-2029 (%)

Figure 06 Peripartum Cardiomyopathy: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 07 Congenital Heart Disease: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 08 Inherited Arrhythmias: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 09 Wearable Cardioverter Defibrillators Market Y-o-Y Growth, By Implant Types, 2021-2029 (%)

Figure 10 Implantable Cardioverter Defibrillator (ICD): Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 11 External Cardioverter Defibrillator: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 12 Wearable Cardioverter Defibrillators Market Y-o-Y Growth, By End-user, 2021-2029 (%)

Figure 13 Home Care settings: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 14 Clinic: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 15 Outpatient Centres: Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 16 Wearable Cardioverter Defibrillators Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 17 North America Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 18 North America Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 19 North America Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 20 North America Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 21 North America Wearable Cardioverter Defibrillators Market Share, By Country, 2021 &amp; 2029(%)

Figure 22 South America Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 23 South America Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 24 South America Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 25 South America Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 26 South America Wearable Cardioverter Defibrillators Market Share, By Country, 2021 &amp; 2029(%)

Figure 27 Europe Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 28 Europe Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 29 Europe Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 30 Europe Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 31 Europe Wearable Cardioverter Defibrillators Market Share, By Country, 2021 &amp; 2029(%)

Figure 32 Asia-Pacific Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 33 Asia-Pacific Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 34 Asia-Pacific Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 35 Asia-Pacific Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 36 Asia-Pacific Wearable Cardioverter Defibrillators Market Share, By Country, 2021 &amp; 2029(%)

Figure 37 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Value, 2019-2029 ($ Million)

Figure 38 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Share, By Conditions, 2021 &amp; 2029(%)

Figure 39 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Share, By Implant Type, 2021 &amp; 2029(%)

Figure 40 Middle East &amp; Africa Wearable Cardioverter Defibrillators Market Share, By End-user, 2021 &amp; 2029(%)

Figure 41 Cardiac Science Corporation: Financials

Figure 42 ZOLL Medical Corporation: Financials

Figure 43 Medtronic: Financials

Figure 44 St. Jude Medical LLC: Financials

Figure 45 Boston Scientific Corporation: Financials

Figure 46 Abbot Medical Optics: Financials

Figure 47 LivaNova Financials

Figure 48 Tianjin JingMing New Tech. Devp. Co., Ltd: Financials

Figure 49 HANSON MEDITEC CO., LTD: Financials

Figure 50 Huaian Meide Medical Instrument Co., Ltd: Financials